Oxford Ebola vaccine trial begins in DRC, targets Bundibugyo strain

• The DRC has reported over 3,200 Ebola cases and more than 1,400 deaths in its 17th outbreak.
• Oxford University's experimental vaccine has reached the clinical trial stage, with several other candidate vaccines being fast-tracked for trials.
• The WHO warns that the true number of cases could be up to four times the official tally in the DRC, highlighting the need for improved detection and testing.

The Democratic Republic of Congo (DRC) has been battling its 17th Ebola outbreak, with over 3,200 confirmed cases and more than 1,400 deaths reported. The central African nation is struggling to contain the epidemic in the conflict-ridden east, where decades of violence have left a scar. Researchers are racing against time to develop a vaccine, with Oxford University announcing that its experimental vaccine has reached the clinical trial stage. The university's Global Chemistry, Manufacturing and Controls (CMC) lead, Pandemic Sciences Institute, Nuffield Department of Medicine, Dr David Pulido-Gomez, credited an 'extraordinary collaborative effort' for achieving this milestone in just eight weeks. Several other candidate vaccines are being fast-tracked for clinical trials, while two potential treatments are also under development.

The outbreak has raised concerns about the need for effective public health regulations and obligations to protect employees and customers. Lawyers advising clients on Ebola-related matters should monitor the development and potential approval of new vaccines and treatments, as these may impact compliance with public health regulations. The World Health Organization (WHO) has warned that the true number of cases could be up to four times the official tally in the DRC, highlighting the need for improved detection and testing. Strikes by healthcare workers demanding unpaid wages have disrupted response efforts in some hospitals, further complicating the situation.

The Ebola outbreak in the DRC has resulted in a significant loss of life, with over 15,000 people killed across Africa over the past 50 years. The Bundibugyo strain of the virus, responsible for this outbreak, has no approved vaccine or treatment. The WHO's emergencies chief warned that underreported cases could exacerbate the situation, emphasizing the need for accurate data and effective response efforts. As researchers work to develop new vaccines and treatments, it is essential to consider the potential impact on public health regulations and obligations, ensuring that compliance with these measures remains a priority.

Lawyers advising clients on Ebola-related matters should monitor the development and potential approval of new vaccines and treatments, as these may impact compliance with public health regulations and obligations to protect employees and customers.

Source: Original reporting via AllAfrica DRC